Exocrine Pancreatic Insufficiency Treatment Market – By Treatment, By Drug Type, By Symptom, By Distribution Channel – Global Forecast, 2024 – 2032

Exocrine Pancreatic Insufficiency Treatment Market Size

The global exocrine pancreatic insufficiency treatment market size was valued at around USD 2.7 billion in 2023 and is estimated to grow at 5.6% CAGR from 2024 to 2032. Exocrine pancreatic insufficiency treatment is composed of both dietary approaches and medical management that aim to compensate for the loss of exocrine pancreatic enzymes, which are important for nutrients digestion and absorption. For patients with this condition, the goal of therapy is the management of symptoms associated with the restraining of nutrients absorption.
 

The increased rate of chronic pancreatitis and cystic fibrosis serves as a significant driver of the exocrine pancreatic insufficiency treatment market, as both lead to dysfunction of the pancreas with consequent enzyme deficiency and digestive problems. For example, in the U.S. alone, the Cystic Fibrosis Foundation estimates that over 40,000 adults and children suffer from this disease, with 105,000 estimated cases recorded across 94 other nations. It is evident that CF does not discriminate by race or ethnicity. In the U.S., patients with CF require long-term treatment with the use of pancreatic enzyme replacement therapy. Hence, the wider the scope of these diseases, the faster the need for new interventions and treatments, for example, PERT that enables patients to maintain their digestive function.

Furthermore, a recent research reports reported that targeted biomarkers may enhance the detection of exocrine pancreatic insufficiency, and the lead time for timely care has improved significantly because there has been technological and diagnostic advancement. Research now seeks to uncover specific biomarkers for enhanced evaluation of pancreatic function. Fecal elastase-1 is one of the many biomarkers widely used for directing clinical assessment of exocrine function, where low fecal elastase-1 concentrations in the stool are suggestive of EPI. This increased accuracy of diagnosis is relevant to the exposure of diagnostic tools necessary in the diagnosis and management of exocrine pancreatic insufficiency (EPI), thus augmenting market development.
 

Exocrine Pancreatic Insufficiency Treatment Market Trends

• The market is one of the fast-moving healthcare markets as a result of the growing aging population base. The world is aging with the older population rapidly increasing, which in turn means the growth of EPI-related diseases cycles including the need for PERT.
   
• For instance, as per the World Health Organization (WHO), there were around 1 billion people aged 60 and above in 2020; this figure is expected to rise to 1.4 billion by 2030 and by 2050, there could be as many as 2.1 billion. Additionally, according to estimates, the population aged 80 years and older could reach 426 million by 2050, which could also triple.
   
• Consequently, this demographic development indicates an increased lack of suitable treatments for moderate health problems related to elders such as EPI, thereby accelerating the growth of the PERT market.
   

Exocrine Pancreatic Insufficiency Treatment Market Analysis

Based on treatment, the market is divided into nutritional management and pancreatic enzyme replacement therapy. The pancreatic enzyme replacement therapy segment dominated the market with the largest revenue of USD 2.3 billion in 2023 and is expected to grow at a significant CAGR over the forecast period.
 

• An increased risk of malnutrition and vitamin deficiency as well as unintentional weight loss, PERT amends the body function of digesting fats and beloved proteins and carbohydrates thus greatly helping in the prevention of putting such risks into place.
   
• Results indicate that PERT is reaching an estimated total of $157.1 billion in 2032; enhanced precision medicine, hosted ambulatory services, diminished side effects, complemented by adaptable dosages appear to endorse wide acceptance of PERT.
   
• PERT is most commonly in the form of capsules or tablets that can be easily incorporated into a person's daily routine and found to have gentle side effects and great acceptance rate with dosage adjustability for precision medicine.

Based on drug type, the exocrine pancreatic insufficiency treatment market is bifurcated into Creon, Zenpep, Pancreaze, Viokace, and other drug types. The Creon segment is projected to account for the largest revenue size of USD 3.6 billion by 2032.
 

• The pancreatic enzyme replacement therapy such as Creon contains a mixture of lipase, protease, and amylase enzymes, which are very important to aid in the digestion of fats, proteins, and carbohydrates. Help improve nutrient uptake and minimize the effects of bloating, steatorrhea, and malnutrition.
   
• Creon ecosystem, use enteric-coated capsules to coat the enzyme to protect it from gastric acid so that it can be released correctly in the small intestine. Different doses of Creon have different requirements for dosage to customize requirements for patients.
   
• With good tolerance and fewer adverse effects, Creon not only enhances the physiology of the digestive system but paves an avenue of improvement in the overall health of EPI patients enhancing nutrition and preventing the adverse effects of poor digestion.
   
• In this regard, Creon is a supportive and effective treatment in the management of EPI, helping patients restore their digestive health.
   

Based on symptom, the exocrine pancreatic insufficiency treatment market is bifurcated into abdominal pain, constipation, diarrhea, fatty stools, weight loss, and other symptoms. The diarrhea segment is projected to grow at a CAGR of 5.9% during the forecast period to reach USD 1.2 billion by 2032.
 

• Diarrhea is the increasingly important and common symptom of EPI which also should serve as an important symptom for helping in the early diagnosis and management of the patient. As per the NIDDK, around 30 percent of EPI patients have chronic diarrhea.
   
• Pertaining to the relief of diarrhea by the practice of PERT or a change in diet, absorption of nutrients and digestion have improved which in a way limits the incidences and severity of such disturbances.
   
• Management of diarrhea when done correctly prevents dehydration and malnourishment hence improving the QOL of people with EPI by improving gastrointestinal stability, better overall health is achieved.
   
• As a result, diarrhea management in EPI patients is important in order to maximize the absorption of nutrients and maintain the digestive system.
   
• When patients are administered treatment such as PERT and given timely diet recommendations, their probability of facing complications significantly decreases, and this ultimately improves their long-term prognosis and quality of life.
   

Based on distribution channel, the exocrine pancreatic insufficiency treatment market is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is projected to grow at a CAGR of 5.4% during the forecast period.
 

• Hospital pharmacists are important in the management of exocrine pancreatic insufficiency, ensuring that patients are able to access essential medications such as pancreatic enzyme replacement therapy when needed.
   
• These pharmacies work with healthcare professionals to modify doses and formulations to best suit each person's requirements.
   
• Hospital pharmacists are expected to help in using the medication, in particular, the timing of doses with meals and the use of other medications to avoid complications.
   
• In addition, these pharmacies ensure timely access to all necessary medications, as well as relay essential information to patients, which increases their compliance with treatment and helps the quality-of-care phosphate respond to the citrate supplement. This also indicates the importance of the Pharmacy Hospitals in controlling the disease and the growing of its market.

The North America region accounted for a 56.9% revenue share in 2023 and is expected to experience substantial growth reaching USD 2.4 billion by 2032.
 

• Even in the global market North America has an upper hand due to the ever-increasing number of EPI patients owing to the robust healthcare system, innovations in pancreatic enzyme replacement therapy, and widespread use of PERT.
   
• Additionally, the best institutions in North America, which hold authority over the medical field, are suggesting further investigations in the field of EPI and pushing for innovative approaches, hence allowing even more for new treatments to be customized.
   
• Also, having well-defined healthcare systems and mandated insurance policies undoubtedly leads to greater penetration of drugs and healthy patient relationships with specialists, resulting in speedy market expansion for people with EPI.
   

The exocrine pancreatic insufficiency treatment market in UK is expected to experience significant and promising growth from 2024 to 2032.
 

• There are many chronic diseases which lead to EPI, including chronic pancreatitis and cystic fibrosis. They have all greatly contributed to the increasing number of patients, all of whom will require a lifetime of PERT.
   
• Furthermore, the UK is also witnessing an increase in the aging population and increasing number of individuals with age-related ailments that can cause a large degree of pancreatic insufficiency, thereby increasing the need for EPI services even further.
   

Japan exocrine pancreatic insufficiency treatment market is anticipated to witness lucrative growth between 2024 – 2032.
 

• The rapid economic growth in Japan is causing a rise in economic activities geared towards increasing spending on healthcare and improving general wellbeing that positively impacts the EPI treatment market. Such economic progress facilitates deployment of advanced therapies and healthcare technologies in EPI management such that the needed innovations are always available to suitable patients when needed.
   
• Also, the increase in the use of telemedicine and digital health technologies within Japan is improving care access and patient interaction. Telehealth and remote monitoring enable EPI patients to gain control of their condition, which helps them stick to a treatment plan and improves people's health. The Japanese EPI treatment market growth will be further boosted by healthcare technology incorporation.
   

The exocrine pancreatic insufficiency treatment market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• Improving infrastructure and legislation, as well as more effective communication campaigns addressing pancreatic disease, will hopefully raise the number of people diagnosed with EPI, thus creating higher demand for treatment options in Eastern KSA. On the other hand, patients with chronic conditions will likely be able to receive treatment due to EPI making more of a focus in the healthcare sector.
   
• As a chronic problem transforming into a more chronic disease, the Saudi Vision 2030 initiative would aggregate EPI treatment methods for chronic disease patients.
   

Exocrine Pancreatic Insufficiency Treatment Market Share

The market for EPI is highly competitive, combining together top global pharma companies and smaller to medium-sized firms competing for market share. The provision and development of novel therapies remains a primary market strategy for these firms. In this case, the development of enzyme therapies using advanced techniques. This is a rapidly changing environment where key players in the industry have considerable power and enable change with extensive investments in new treatments which focus on improving outcomes and the clinical experience for patients. Geographically, as regulations evolve and demand for EPI treatment becomes more prevalent, collaborations, mergers, and acquisitions form a crucial part of our growth strategy.
 

Exocrine Pancreatic Insufficiency Treatment Market Companies

Some of the eminent market participants operating in the exocrine pancreatic insufficiency treatment industry include:

• Abbott Laboratories
• AbbVie
• Digestive Care
• Essential Pharma
• Nestle
• Nordmark Pharma
• Sun Pharmaceutical Industries
• Viatris
• Vivus
• Zentiva Pharma UK
   

• Abbott Laboratories, new therapies for EPI are being promoted together with Abbott Laboratories, as the company believes that with its active global representation and focus on patient education, the level of awareness will increase and access to treatments will broaden.
   
• AbbVie, the company has positioned well in the global market because of its unwavering support for research and development, which has resulted in an avalanche of advanced medicines that one can use in the treatment of EPI.
   
• Nordmark Pharma, pancreatic Enzyme Therapeutics is what Nordmark pursues within the pharmaceutical industry, but what really stands out is the fact that they strive for top quality, which leads to great products in terms of potency profile consistency.
   

Exocrine Pancreatic Insufficiency Treatment Industry News:

• In February 2023, Nestle Health and Codexis, Inc. announced positive Phase 1 results for CDX-7108, validating their collaboration and strengthening their position in enzyme therapy ahead of the planned Phase 2 study in early 2024.
• In January 2020, Nestlé S.A. announced that it had entered into an asset purchase agreement with Allergan plc to acquire the gastrointestinal medication Zenpep. This acquisition was aimed at strengthening Nestlé S.A.'s medical nutrition business and expanding its portfolio of therapeutic products.

The exocrine pancreatic insufficiency treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment

• Nutritional management
• Pancreatic enzyme replacement therapy (PERT) 

Market, By Drug Type

• Creon
• Zenpep
• Pancreaze
• Viokace
• Other drug types               

Market, By Symptom

• Abdominal pain
• Constipation
• Diarrhea
• Fatty stools
• Weight loss
• Other symptoms                        

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies                      

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE